Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- mortality
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Detailed Description
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Investigators
Hasan Onal
Professor
Kanuni Sultan Suleyman Training and Research Hospital
Eligibility Criteria
Inclusion Criteria
- •accepted to participate with an informed consent
- •proven positive COVID-19
Exclusion Criteria
- •declined to participate
- •genetic/chromosomal abnormalities
- •any kind of history of previous adverse events with transfusion
- •diagnosis of immune deficiency
Outcomes
Primary Outcomes
mortality
Time Frame: 4 months
mortality rates in two groups will be compared